Oral Gemifloxacin Versus Intravenous Cefotaxime in Treatment of Spontaneous Bacterial Peritonitis

Tanta University

Status and phase: Enrolling; Phase 3

Conditions: Spontaneous Bacterial Peritonitis

Treatments: Drug: Cefotaxime; Drug: Gemifloxacin

Study type: Interventional

Funder types: Other

Identifiers

NCT04168099

SBP new treatment

Details and patient eligibility

About

oral Gemifloxacin versus intravenous Cefotaxime in treatment of spontaneous bacterial peritonitis

Full description

Comparative Study between the Efficacy of oral Gemifloxacin and intravenous Cefotaxime in treatment of spontaneous bacterial peritonitis

Enrollment: 60 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with spontaneous bacterial peritonitis

Exclusion criteria

• secondary peritonitis

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

60 participants in 2 patient groups

Cefotaxime

Experimental group

Description:

Cefotaxime intravenous

Treatment:

Drug: Cefotaxime

Gemifloxacin

Active Comparator group

Description:

Oral Gemifloxacin

Treatment:

Drug: Gemifloxacin